Moneycontrol
Last Updated : May 20, 2015 02:58 PM IST | Source: CNBC-TV18

Aim for 20% revenue growth in FY16: Mangalam Drugs Organic

Mangalam Drugs Organic is into manufacturing APIs for malaria & HIV drugs and is the world's largest manufacturer of anti-malarial APIs.


Talking about the business outlook for the next fiscal, Govardhan Dhoot, MD, Mangalam Drugs & Organics in an interview to CNBC-TV18 said currently they are awaiting World Health Organisation (WHO) approvals for new malaria and HIV molecules and are likely to get the approval by December.


He said they are targeting a 20 percent revenue growth in FY16. The company is also looking at inorganic opportunities, said Dhoot.


The company is into manufacturing APIs for malaria & HIV drugs and is the world's largest manufacturer of anti-malarial active pharmaceutical ingredient (APIs) with manufacturing facilities in Vapi, Gujarat.


The company has 50-60% market share in the anti-malaria space with clients such as Ajanta Pharma, Cipla, Sanofi, Novartis, and IPCA.


The company is in pact with Bill Gates Foundation for supply of anti-malarial drugs worldwide and has a WHO Good manufacturing practices (GMP) certificate for the API plant. However, Dhoot clarified that there is no financial considerations for this tie-up.

For the entire interview watch video

First Published on May 20, 2015 02:58 pm
More From
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant